Merkouris, Spyros , Barde, Yves-Alain , Binley, Kate E. , Allen, Nicholas D. , Stepanov, Alexey V. , Wu, Nicholas C. , Grande, Geramie , Lin, Chih-Wei , Li, Meng , Nan, Xinsheng , CHACON FERNANDEZ, PEDRO JOSE, DiStefano, Peter S. , Lindsay, Ronald M. , Lerner, Richard A. , Xie, Jia
No
Proc. Natl. Acad. Sci. U. S. A.
Article
Científica
9.58
24/07/2018
000439574700009
The diverse physiological roles of the neurotrophin family have long prompted exploration of their potential as therapeutic agents for nerve injury and neurodegenerative diseases. To date, clinical trials of one family member, brain-derived neurotrophic factor (BDNF), have disappointingly failed to meet desired endpoints. Contributing to these failures is the fact that BDNF is pharmaceutically a nonideal biologic drug candidate. It is a highly charged, yet is a net hydrophobic molecule with a low molecular weight that confers a short t(1/2) in man. To circumvent these shortcomings of BDNF as a drug candidate, we have employed a function-based cellular screening assay to select activating antibodies of the BDNF receptor TrkB from a combinatorial human short-chain variable fragment antibody library. We report here the successful selection of several potent TrkB agonist antibodies and detailed biochemical and physiological characterization of one such antibody, ZEB85. By using a human TrkB reporter cell line and BDNF-responsive GABAergic neurons derived from human ES cells, we demonstrate that ZEB85 is a full agonist of TrkB, comparable in potency to BDNF toward human neurons in activation of TrkB phosphorylation, canonical signal transduction, and mRNA transcriptional regulation.
antibody; TrkB; agonist; combinatorial library; membrane tethered